Neil Averitt commentary: AbbVie teaches remedies should focus on individual wrongdoers

Washington, D.C. (August 7, 2018) -- In its recent challenge to bad-faith litigation by the AbbVie pharmaceutical corporation, the Federal Trade Commission set out an important and welcome marker on the merits, but it missed an opportunity to rethink the most effective remedies for serious corporate wrongdoing....

Related Sections